Pan-cancer treatment selection test

Our technology offers comprehensive genomic profiling of tumors. Together with clinicians, we use a robust pharmacogenomics database to harness the information needed for accurate diagnosis in just 4 weeks. This allows for tailored and targeted therapy and immunotherapy suggestions, reducing potential side effects and shortening recovery time.

Contact For More Information

About CoGenesis® Cancer

Thousands can benefit

Our testing is designed for cancer patients who are not responding to conventional cancer therapies and patients looking for personalised therapies based on their genetic profiles. We provide the information needed about the molecular subtypes of a patient’s tumour.

Changing our understanding

Traditionally, cancers have been classified by the location of tumours within the body, with underlying DNA mutations overlooked. Research shows that the same set of DNA mutations can cause multiple cancer types, and when these are identified, more effective treatments can be selected based on an individual’s genetic profile.

The process

1

A tumor or a blood biopsy sample is taken.

2

The sample then undergoes targeted next-generation sequencing.

3

Mutations are identified and confirmed by complimentary technologies.

4

Evidence-based targeted treatments are recommended.

Technical Specification

Reports immunotherapy biomarkers – analysis of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) status

Simultaneous profiling of DNA and RNA variants

Structural variations and fusions detection using RNA

Actionable insights according to international guidelines

Unique Molecular Identifier (UMI) to reduce sequencing errors

Market-leading accuracy: SNV 99.5%, Indel 96.5%, TMB 95.4%

Detection level as low as 1.3%

Joined the first NG EQA program by UK NEQAS

A high accuracy standard

Steps	Accuracy
DNA sequencing	99.9%
Variant calling – SNP	>99%^*^#
Variant calling – Indel	>99%^*^#

Steps

Accuracy

DNA sequencing

99.9%

Variant calling – SNP

>99%^*^#

Variant calling – Indel

>99%^*^#

* Passed GenQA/UK NEQAS external quality assurance

# The interpretation of sequencing variants is based on the current understanding of the variants at the time it was observed, which may change over time as more information about the genes becomes available. Not all variants are represented in this report.

CoGenesis® Cancer

Pan-cancer treatment selection test

About CoGenesis® Cancer

Thousands can benefit

Our testing is designed for cancer patients who are not responding to conventional cancer therapies and patients looking for personalised therapies based on their genetic profiles. We provide the information needed about the molecular subtypes of a patient’s tumour.

Changing our understanding

Comprehensive DNA & RNA sequencing of

523

cancer-related genes

Specific markers for

9

major cancer types

Covering up to

18

FDA-approved or experimental targeted therapies

The process

1

A tumor or a blood biopsy sample is taken.

2

The sample then undergoes targeted next-generation sequencing.

3

Mutations are identified and confirmed by complimentary technologies.

4

Evidence-based targeted treatments are recommended.

Technical Specification

Reports immunotherapy biomarkers – analysis of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) status

Simultaneous profiling of DNA and RNA variants

Structural variations and fusions detection using RNA

Actionable insights according to international guidelines

Unique Molecular Identifier (UMI) to reduce sequencing errors

Market-leading accuracy: SNV 99.5%, Indel 96.5%, TMB 95.4%

Detection level as low as 1.3%

Joined the first NG EQA program by UK NEQAS

Targeted cancer therapy can improve overall lung cancer survival rates up to 8 times.

A high accuracy standard

Pinpointing genetic uniqueness